A COST-EFFECTIVESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN PORTUGAL

被引：0
|
作者：
Silva Miguel, L. [1 ]
Pinheiro, B. [1 ]
Lopes, R. [1 ]
Revil, C. [2 ]
Monteiro, I [3 ]
Borges, M. [4 ]
机构：
[1] Univ Lisbon, Ctr Estudos Med Baseada Evidencia, Fac Med, Lisbon 11, Portugal
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Roche Farmaceut Quim Lda, Amadora, Portugal
[4] Univ Lisbon, Lab Farmacol Clin & Terapeut, Fac Med, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB51
引用
收藏
页码：S69 / S70
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
    Garrison, Louis R., Jr.
    Lubeck, Deborah
    Lalla, Deepa
    Paton, Virginia
    Dueck, Amylou
    Perez, Edith A.
    CANCER, 2007, 110 (03) : 489 - 498
  • [32] Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
    Tolaney, Sara M.
    Tayob, Nabihah
    Dang, Chau
    Yardley, Denise A.
    Isakoff, Steven J.
    Valero, Vicente
    Faggen, Meredith
    Mulvey, Therese
    Bose, Ron
    Hu, Jiani
    Weckstein, Douglas
    Wolff, Antonio C.
    Reeder-Hayes, Katherine
    Rugo, Hope S.
    Ramaswamy, Bhuvaneswari
    Zuckerman, Dan
    Hart, Lowell
    Gadi, Vijayakrishna K.
    Constantine, Michael
    Cheng, Kit
    Briccetti, Frederick
    Schneider, Bryan
    Garrett, Audrey Merrill
    Marcom, Kelly
    Albain, Kathy
    DeFusco, Patricia
    Tung, Nadine
    Ardman, Blair
    Nanda, Rita
    Jankowitz, Rachel C.
    Rimawi, Mothaffar
    Abramson, Vandana
    Pohlmann, Paula R.
    Van Poznak, Catherine
    Forero-Torres, Andres
    Liu, Minetta
    Ruddy, Kathryn
    Zheng, Yue
    Rosenberg, Shoshana M.
    Gelber, Richard D.
    Trippa, Lorenzo
    Barry, William
    DeMeo, Michelle
    Burstein, Harold
    Partridge, Ann
    Winer, Eric P.
    Krop, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) : 2375 - +
  • [33] Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer
    Konishi, Takaaki
    Fujiogi, Michimasa
    Michihata, Nobuaki
    Ohbe, Hiroyuki
    Matsui, Hiroki
    Fushimi, Kiyohide
    Tanabe, Masahiko
    Seto, Yasuyuki
    Yasunaga, Hideo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1115 - 1123
  • [34] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE FOR THE ADJUVANT TREAT OF PATIENTS WITH RESIDUAL INVASIVE HER2+EARLY BREAST CANCER IN GREECE
    Naoum, V
    Antonaki, M.
    Kakouros, M.
    Hansen, S. A.
    Ouzounelli, M.
    Tziarou, N.
    VALUE IN HEALTH, 2022, 25 (12) : S173 - S173
  • [35] Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis
    Mano, Max S.
    Loibl, Sibylle
    Mamounas, Eleftherios P.
    von Minckwitz, Gunter
    Huang, Chiun-Sheng
    Untch, Michael
    Wolmark, Norman
    Wapnir, Irene L.
    Yang, Youngsen
    Conlin, Alison K.
    Kuemmel, Sherko
    Saghatchian, Mahasti
    DiGiovanna, Michael P.
    Strunk, Claudia
    Zimovjanova, Martina
    Song, Chunyan
    Liu, Haying
    Tesarowski, David
    Blotner, Steven
    Lam, Lisa H.
    Smitt, Melanie
    Geyer, Charles E., Jr.
    CANCER RESEARCH, 2020, 80 (04)
  • [36] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    WOMENS HEALTH, 2009, 5 (02) : 135 - 147
  • [37] Development of trastuzumab emtansine (Kadcyla®) for thetreatment of HER2-positive breast cancer
    Phillips, Gail
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [38] Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
    Mano, Max S.
    FUTURE ONCOLOGY, 2020, 16 (32) : 2595 - 2609
  • [39] Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
    Sadeghi, Saeed
    Olevsky, Olga
    Hurvitz, Sara A.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 329 - 338
  • [40] Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
    Recondo, Gonzalo, Jr.
    de la Vega, Maximo
    Galanternik, Fernando
    Diaz-Canton, Enrique
    Amadeo Leone, Bernardo
    Leone, Jose Pablo
    CANCER MANAGEMENT AND RESEARCH, 2016, 8 : 57 - 65
12345